These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38332554)

  • 1. Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno-inflammatory diseases.
    Maleki F; Clark E; Banfield C; Byon W; Nicholas T
    CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):551-562. PubMed ID: 38332554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients.
    Hughes JH; Qiu R; Banfield C; Dowty ME; Nicholas T
    Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1447-1456. PubMed ID: 36045513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
    Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
    Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
    Vong C; Martin SW; Deng C; Xie R; Ito K; Su C; Sandborn WJ; Mukherjee A
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.
    Wang K; Feng L; Zhang J; Zou Q; Xu F; Sun Z; Tang F; Chen L
    Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.
    Hua F; Ribbing J; Reinisch W; Cataldi F; Martin S
    Br J Clin Pharmacol; 2015 Jul; 80(1):101-9. PubMed ID: 25614144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of axitinib in healthy volunteers.
    Garrett M; Poland B; Brennan M; Hee B; Pithavala YK; Amantea MA
    Br J Clin Pharmacol; 2014 Mar; 77(3):480-92. PubMed ID: 23834452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers.
    Baek IH; Back HM; Chae JW; Ha ES; Park H; Choi DH; Staatz CE; Kim MS
    Biopharm Drug Dispos; 2021 Mar; 42(2-3):94-102. PubMed ID: 33527395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
    Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
    J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.
    Piotrovsky VK; Huang ML; Van Peer A; Langenaecken C
    Cancer Chemother Pharmacol; 1998; 42(3):221-8. PubMed ID: 9685057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a
    Qiu R; Sharma R; Wei H; Kirkovsky L; Zhou Y; Martin DDA; Banfield C; Dowty ME
    Br J Clin Pharmacol; 2023 Oct; 89(10):3056-3066. PubMed ID: 37183779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
    Ou YC; Liu L; Tariq B; Wang K; Jindal A; Tang Z; Gao Y; Sahasranaman S
    Clin Transl Sci; 2021 Mar; 14(2):764-772. PubMed ID: 33306268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
    Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
    Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
    Yang S; Lukey P; Beerahee M; Hoke F
    Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Modelling of Acetaminophen and Ibuprofen: the Influence of Body Composition, Formulation and Feeding in Healthy Adult Volunteers.
    Morse JD; Stanescu I; Atkinson HC; Anderson BJ
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):497-507. PubMed ID: 35366213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer.
    Gupta A; Jarzab B; Capdevila J; Shumaker R; Hussein Z
    Br J Clin Pharmacol; 2016 Jun; 81(6):1124-33. PubMed ID: 26879594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites.
    Willavize S; Fiedler-Kelly J; Ludwig E; Guan L
    J Clin Pharmacol; 2017 Feb; 57(2):255-265. PubMed ID: 27436172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.